In a large study in adult patients with rheumatoid arthritis, van Vollenhoven et al. reported an incidence of hypogammaglobulinemia of 24% with IgM and IgG below the normal values for at least 4 months after the last cycle of rituximab (van Vollenhoven et al., 2015). Here, CD40LG is linked to rheumatoid arthritis.